long-term planning

Calysta acquires BioProtein in Norway

CALYSTA Energy Inc. announced the acquisition of BioProtein A/S based in Stavanger, Norway.

Through this acquisition, Calysta will enter the rapidly growing, $370 billion market for fish and livestock feed and feed additives. Calysta develops novel natural gas conversion technology using methane for high-value chemicals and fuels.

According to the announcement, the BioProtein technology is the only commercial-scale process available to directly convert natural gas into biological products. The protein feed produced using BioProtein’s technology is the only feed for the production of fuels and chemicals technologies using methane as a feedstock. Biocatalysis and Biological Gas-to-Chemicals technologies using methane as a feedstock.

Calysta’s broad capabilities in synthetic biology and biocatalysis and the knowledge of its Biological Gas-to-Liquids units. Calysta Energy will continue to reflect the new multi-industry focus, including its capabilities in synthetic biology and biocatalysis roles with the new entity. Both companies Calysta’s broad capabilities in synthetic biology and biocatalysis terms were not disclosed.

Calysta chairman, president and chief executive officer. "Demand is strong in the commercial fish and agriculture market for new sustainable protein sources. BioProtein’s expertise in process technology and nutrition metabolism in animal health complements Calysta's broad capabilities in synthetic biology and biocatalysis for development of methane as a new biological feedstock."

Calysta said it expects to evaluate construction of a manufacturing facility in the U.S. as part of the acquisition and to reflect the new multi-industry focus, Calysta Energy said it is changing its name to Calysta Inc. The new company will have two primary business units. Calysta Energy will continue the current programs in development of its Biological Gas-to-Liquids and Biological Gas-to-Chemicals technologies using methane as a feedstock for the production of fuels and chemicals. Calysta Nutrition will focus on the development of a range of nutritional products from methane.

Shaw will continue in his current roles with the new entity. Both companies are privately held. Further terms were not disclosed.

losses from the disease, improved bird performance and better profits for producers.

References
Cookson, K., et al. 2013. Effect of lasalocid or salinomycin on performance and immunity following coccidia vaccination of commercial broilers. American Veterinary Medical Association. convention notes; American Association of Avian Pathologists Symposium. Pflizer study #03-11.7AMVQ.


*Dr. Donald Waltrip is a senior technical services veterinarian at Zoetis Inc.

PROBLEM

Small amounts of β-mannans in soybean meal can waste valuable energy in poultry.

A few facts you should know about β-mannans in feed and how it affects poultry:

FACT: β-mannans (beta-galactomannans) are an antinutritive fiber found in soybean meal.

FACT: The animal’s innate immune system recognizes β-mannans as an invading pathogen and initiates a protective action called the Feed-Induced Immune Response (FIIR).

FACT: This innate immune response diverts energy away from growth and performance.

By breaking down β-mannans, Hemicell® minimizes the Feed-Induced Immune Response (FIIR) to spare more energy for performance. Hemicell is a unique and patented energy-sparing enzyme for your animal’s diet.

FACT: Hemicell breaks down β-mannans in soybean meal.

FACT: Once broken down, β-mannans no longer trigger the Feed-Induced Immune Response (FIIR).

FACT: Hemicell allows more energy to be available for growth and performance.